Single-Shot Versus Focal Dual-Energy Pulsed Field-Based Ablation for Atrial Fibrillation
- Sponsor
- Marien Hospital Herne
- Study ID
- NCT07783919
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Atrial Fibrillation (AF)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Catheter Ablation for Atrial Fibrillation — PROCEDUREPFA-based Catheter Ablation for Atrial Fibrillation (PFA single shot vs. focal dual-eregy)
Study Details
Comparison of single-shot PFA systems with focal dual-energy (PFA/RF) in patients at high risk of atrial fibrillation recurrence.
Key Dates
- First listed
- Aug 25, 2026
- Start date
- Sep 1, 2026
- Status verified
- Aug 2026
- Primary completion
- Aug 31, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 268 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Single shot PFA-based Ablation for AF
- Placebo Comparator: Focal Dual-Energy-based Ablation for Atrial Fibrillation
Primary Outcome Measure
Freedom from atrial arrhythmias during follow-up [ Time Frame: 365 days, excluding the blanking period ]
Central Contacts
- Dimitrios Bismpos, Dr.med.+49023234995609
Related Studies
- Cardiovascular Innovation & Research Institute 's NEXUS Registry, the Whole is Greater Than the Parts.Recruiting · Cardiovascular Innovation and Research Institute · Glenwood Springs, Colorado
- KardiaMobile ECG Monitoring Effects on Health Care Utilization and Patient Experience With Atrial FibrillationEnrolling By Invitation · Northwestern University · Chicago, Illinois
- Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)PHASE3 · Recruiting · Anthos Therapeutics, Inc. · Birmingham, Alabama
- Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial FibrillationEARLY_PHASE1 · Recruiting · China National Center for Cardiovascular Diseases · Boston, Massachusetts